Mission

Arterium Medical’s mission is the early identification of life-threatening circulatory collapse that requires urgent intervention such as in sepsis, cardiac shock or internal bleeding.

Current Status

NIH has funded, through several grants, the development and refinement of the disposable sensor technology. With this patented technology, for the first time, clinically proven ultrasound can be implemented as a simple low-cost monitoring device.

The first clinical test of the ultrasound monitoring device as a peri-operative tool is scheduled for this fall (2015) and has been funded by a recent NIH grant.

Clinical Focus - Sepsis

Our clinical focus addressed the potential of saving lives in a disease with high incidence and high mortality rate, with early adoption driven by reimbursement/financial incentives, an FDA 510(k) clearance and effective time to market.

Arterium Medical’s initial clinical focus is sepsis: the leading cause of in-hospital mortality with death being eight times as likely from sepsis compared with other diagnoses.[1] The number of in-hospital deaths from sepsis has not appreciably declined in the last decade despite an 11% annual increase in expenditure.[2] The 2011 hospital cost of treating sepsis was $20 billion with the cost per stay the same as treating acute myocardial infarction - heart attacks.[2]

The chance of surviving sepsis is increased significantly with early aggressive treatment.[1] However, early detection can be problematic - a review by Kaiser Permanente indicated that more than half of patients who ultimately died of sepsis did not initially present with the typical symptoms – falling blood pressure and elevated lactates.[3]

Arterium Medical believes that the acute inflammation associated with sepsis which results in compromised capillary perfusion [4] can be detected by changes in the peripheral arterial circulation. We further believe that our sensor can more quickly and consistently detect these changes, allowing health care personnel to identify and effectively treat sepsis before organ failure occurs.

Business Model
Arterium Medical’s business model is similar to that of pulse oximetry – a low cost, easy-to-use clinical monitoring tool to identify potentially life-threatening circumstances. Pulse Oximetry has become a $1B+ global business.

The compelling financial motivation for early adoption is that hospitals are NOT reimbursed for infection/sepsis treatment when the patient develops infection during their in-hospital stay. Our clinical partners indicate that a “pulse oximetry like” device would be clinically beneficial and assure reimbursement in Emergency and Critical Care, long-term care facilities and skilled nursing facilities where care-site acquired infection is most prevalent.

Patented Technology
Arterium Medical’s non-invasive disposable sensor technology implements well understood ultrasound measurement of blood flow that, now for the first time, can be used to transdermally monitor peripheral arterial blood flow continuously. The unique thin film sensor design and construction using co-polymer materials is protected by three U. S. patents.

An FDA 510(k) clearance is expected considering the predicate ultrasound devices – now with our unique capability of continuous ultrasound measurements over several hours.

Who We Are
Arterium Medical, LLC, an early stage medical device company incorporated in Delaware, is planning to establish an engineering and pilot manufacturing facility in Princeton, NJ.

The founding team brings together experienced executives from the medical device industry with demonstrated skills in product development and launch, ultrasound devices, FDA regulatory and quality considerations and financial/legal management.

Arterium Medical’s sensor technology and understanding of clinical uses has been developed by our research partner, DVX LLC, under several NIH grants. Arterium Medical has the exclusive license to intellectual property of interest developed by DVX. Our office is co-located with DVX in Princeton, NJ.

Contact info:
Dr. John Turner, Ph.D., MBA
CEO and President
w: 609-819-2600
c: 303-588-8580

 [1] NCHS Data Brief No. 62, June 2011, Inpatient Care for Septicemia or Sepsis: A Challenge for Patients and Hospitals.      http://www.cdc.gov/nchs/data/databriefs/db62.pdf

[2] Agency for Healthcare Research and Quality, HCUP Costs for Hospital Stays in the United States, 2011, Dec 2013.     http://www.hcup-us.ahrq.gov/reports/statbriefs/sb168-Hospital-Costs-United-States-2011.pdf

[3] Lui, Vincent MD, et. al., Hospital Deaths in Patients with Sepsis From 2 Independent Cohorts, JAMA 2014; 312(1): 90-92.      http://jama.jamanetwork.com/article.aspx?articleid=1873131

[4] Granger, DN, Senchenkova, E., Capillary Perfusion, Chapter 5, Inflammation and the Microcirculation, San Rafael (CA): Morgan & Claypool Life Sciences; 2010.      http://www.ncbi.nlm.nih.gov/books/NBK53375/